Combining antibiotics remains a promising approach to treat patients and to prevent the emergence of antimicrobial resistance
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout

Change history
09 April 2025
A Correction to this paper has been published: https://doi.org/10.1038/s41564-025-02003-w
References
AMR-X Collaborators. Lancet Microbe 5, e500–e507 (2024).
Antimicrobial Resistance Collaborators et al. Lancet 399, 629–655 (2022).
Kerantzas, C. A. & Jacobs, W. R. mBio 8, e01586–16 (2017).
Poespoprodjo, J. R., Douglas, N. M., Ansong, D., Kho, S. & Anstey, N. M. Lancet 402, 2328–2345 (2023).
Goldstein, B. P. J. Antibiot. 67, 625–630 (2014).
Docobo-Pérez, F. et al. Antimicrob. Agents Chemother. 59, 5602–5610 (2015).
Howard, A. et al. Lancet Infect. Dis. 24, e47–e58 (2024).
Darlow, C. A. et al. Antimicrob. Agents Chemother. 65, e00293–21 (2021).
Abou Fayad, A. et al. BMJ Glob. Health 7, e010863 (2023).
Gowrisankar, G. et al. Sci. Data 4, 170135 (2017).
Nellums, L. B. et al. Lancet Infect. Dis. 18, 796–811 (2018).
Bokhary, H., Pangesti, K. N. A., Rashid, H., Abd El Ghany, M. & Hill-Cawthorne, G. A. Trop. Med. Infect. Dis. 6, 11 (2021).
Higgins, K. Regulatory Overview of Adequate and Well-Controlled Studies in TB Regimen Development (FDA, 2018).
Paul, M. et al. Lancet Infect. Dis. 18, 391–400 (2018).
Walker, A. S. et al. Lancet Infect. Dis. 21, e175–e181 (2021).
Acknowledgements
This work was supported in part by UKRI 107136 36348 (to W.H.) and Wellcome Trust grant ref: 226691/Z/22/Z (to W.H., A.H. and A.G.). C.A.D. is funded by the NIHR (Award Ref. CL-2022-07-001). Pre-X refers to a movement of scientists who are interested in feeding the pipeline of new antibacterial agents towards agencies such as CARB-X, as well as optimizing the use and combinations of existing agents).
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
W.H. holds or has recently held research grants with UKRI, EU (FP7, IMI-1, IMI-2), Wellcome, F2G, Spero Therapeutics, Antabio, Pfizer, Allecra, Bugworks, Phico Therapeutics, BioVersys and the Global Antibiotic Research and Development Partnership (GARDP). He is (or has recently been) a consultant for Appili Therapeutics, F2G, Spero Therapeutics, Pfizer, GSK, Phico Therapeutics, Pulmocide and Mundipharma Research Ltd. He was a member of the Specialist Advisory Committee for GARDP (2020–2023), a member of the British Society for Antimicrobial Chemotherapy (BSAC) Breakpoint Committee (2020–2023), a member of Health Technology Appraisal (HTA) Prioritisation Committee for Hospital Care (2022–2024) and was the Specialty National Co-lead for Infection for the National Institute of Health Research (NIHR) (2020–2024). I.B. was Chief Data Scientist Advisory for AstraZeneca (2019–2023). S.N. is an employee of Johnson and Johnson; her views are her own and do not necessarily represent those of her employer. A.H. declares past personal consulting work for Pfizer outside the submitted work, and a donation from Pfizer to the University of Liverpool for a public and professional engagement project outside the submitted work. The other authors declare no competing interests.
Peer review
Peer review information
Nature Microbiology thanks the anonymous reviewers for their contribution to the peer review of this work.
Rights and permissions
About this article
Cite this article
Hope, W., Nambiar, S., O’Brien, S. et al. Combining antibiotics to tackle antimicrobial resistance. Nat Microbiol 10, 813–816 (2025). https://doi.org/10.1038/s41564-025-01969-x
Published:
Issue date:
DOI: https://doi.org/10.1038/s41564-025-01969-x